Velaga V. Appalaraju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Velaga V. Appalaraju has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Babu Ramanathan
Department of Veterinary & Biomedical Sciences College of Veterinary Medicine University of Minnesota at Twin Cities Saint Paul Minnesota USA
1 shared publication- Chit Laa Poh
ALPS Global Holding Berhad, The ICON, East Wing Tower, No. 1, Jalan 1/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia
1 shared publication Fadhiratul Hashmin Jafry
Faculty of Pharmacy, MAHSA University, Malaysia
1 shared publication- Malihe Masomian
Research and Development Department Pure Biologics SA Legnicka Wroclaw Poland
1 shared publication - Michelle Felicia Lee
Faculty of Medical and Life Sciences, Department of Biomedical Sciences, Jeffrey Cheah Sunway Medical School, Sunway University, Sunway City, Malaysia
1 shared publication Nahlah E. Ismail
Faculty of Pharmacy, MAHSA University, Malaysia
1 shared publication
Latest Publications
- Open Access
- 15 January 2025
- Published by HH Publisher in Progress In Microbes & Molecular Biology
- Vol. 8 (1)
Anti-Dengue Activity of Revaprazan Hydrochloride: A Repurposed Drug Candidate
Dengue fever is a major health problem, and there are no vaccines or effective antiviral treatments. Drug repurposing is a quick and appealing innovative therapeutic strategy. This study aims to develop a potent anti-dengue drug for the treatment of dengue infections. In this study, we screened a library containing 174 compounds using foci-forming unit reduction and quantitative real-time polymerase chain reaction assays. Revaprazan hydrochloride showed the most potent anti-dengue activity and low cytotoxicity in Vero cells with a half-maximal inhibitory concentration (IC50) of 1.36 ± 0.16 µM, and a half-maximal cytotoxicity concentration (CC50) of 42.41 ± 0.05 µM. Revaprazan hydrochloride revealed 98.31% virucidal activity and 99.80% for post-infection activity against dengue virus serotype 3 (DENV-3). Revaprazan hydrochloride required only 5 min to exert its virucidal effects after contact with DENV-3. Time-of-drug addition and time-of-drug elimination assays indicated that revaprazan hydrochloride was able to interfere with the early stage of DENV-3 infection. In silico studies demonstrated that revaprazan hydrochloride had strong binding energy to the RNA-dependent RNA polymerase domain of the NS5 and the helicase domain of the NS2B/NS3 protein. DENV-3 showed no resistance up to 25 passages in the presence of revaprazan hydrochloride. Revaprazan hydrochloride showed varying inhibitory effects against all four dengue virus serotypes. Overall, revaprazan hydrochloride is a novel dengue virus inhibitor and could serve as a promising antiviral drug for further preclinical evaluations.
- 15 January 2025
- Published by HH Publisher in Progress In Microbes & Molecular Biology
- Vol. 8 (1)
Open AccessAnti-Dengue Activity of Revaprazan Hydrochloride: A Repurposed Drug Candidate
Dengue fever is a major health problem, and there are no vaccines or effective antiviral treatments. Drug repurposing is a quick and appealing innovative therapeutic strategy. This study aims to develop a potent anti-dengue drug for the treatment of dengue infections. In this study, we screened a library containing 174 compounds using foci-forming unit reduction and quantitative real-time polymerase chain reaction assays. Revaprazan hydrochloride showed the most potent anti-dengue activity and low cytotoxicity in Vero cells with a half-maximal inhibitory concentration (IC50) of 1.36 ± 0.16 µM, and a half-maximal cytotoxicity concentration (CC50) of 42.41 ± 0.05 µM. Revaprazan hydrochloride revealed 98.31% virucidal activity and 99.80% for post-infection activity against dengue virus serotype 3 (DENV-3). Revaprazan hydrochloride required only 5 min to exert its virucidal effects after contact with DENV-3. Time-of-drug addition and time-of-drug elimination assays indicated that revaprazan hydrochloride was able to interfere with the early stage of DENV-3 infection. In silico studies demonstrated that revaprazan hydrochloride had strong binding energy to the RNA-dependent RNA polymerase domain of the NS5 and the helicase domain of the NS2B/NS3 protein. DENV-3 showed no resistance up to 25 passages in the presence of revaprazan hydrochloride. Revaprazan hydrochloride showed varying inhibitory effects against all four dengue virus serotypes. Overall, revaprazan hydrochloride is a novel dengue virus inhibitor and could serve as a promising antiviral drug for further preclinical evaluations.
- Open Access
- 1 January 2018
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9
Phytochemical screening and evaluation of anti-inflammatory of activity of Gardenia carinata leaves
Background Gardenia carinata plant has wide range of therapeutic uses such as anti-HIV, cytotoxic, antimicrobial and mosquito larvicidal activities. The purpose of this study is to determine phytochemical screening and anti-inflammatory activity of different organic extracts of G. carinata leaves. Methods The leaf extracts were prepared using different organic solvents in the order of increasing polarity chloroform, methanol and distilled water by using soxhlet extraction method. The extract was characterized by Shinoda test, Salkowski test, ferric chloride test, Folin-Ciocalteau test and foam test. The anti-inflammatory activity of the entire G. carinata leaf extracts were evaluated at a dose level of 100 mg/kg (bw), orally by using Carrageenan-induced paw oedema method. Indomethacin 10 mg/kg (bw) was used as positive control. Paw thickness of rats were monitored every hour post oedema induction for 5 hours and the percentage of inhibited oedema were calculated. Results The inhibitory percentage exhibited by Gardenia carinata water extract (GCWE) was 32.66%, G. carinata methanol extract (GCME) was 27.98% and G. carinata chloroform extract (GCCE) 24.41% respectively. All these groups are significantly differenced in inhibition when compared with indomethacin inhibition percentage 39.33% at the fifth hour (p < 0.05). Extracts of G. carinata leaves revealed the presence of flavonoids, terpenoids, tannins, phenolic compounds and saponins. Conclusion Gardenia carinata leaves showed the anti-inflammatory activity in carrageenan-induced rat paw oedema model.
- 1 January 2018
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9
Open AccessPhytochemical screening and evaluation of anti-inflammatory of activity of Gardenia carinata leaves
Background Gardenia carinata plant has wide range of therapeutic uses such as anti-HIV, cytotoxic, antimicrobial and mosquito larvicidal activities. The purpose of this study is to determine phytochemical screening and anti-inflammatory activity of different organic extracts of G. carinata leaves. Methods The leaf extracts were prepared using different organic solvents in the order of increasing polarity chloroform, methanol and distilled water by using soxhlet extraction method. The extract was characterized by Shinoda test, Salkowski test, ferric chloride test, Folin-Ciocalteau test and foam test. The anti-inflammatory activity of the entire G. carinata leaf extracts were evaluated at a dose level of 100 mg/kg (bw), orally by using Carrageenan-induced paw oedema method. Indomethacin 10 mg/kg (bw) was used as positive control. Paw thickness of rats were monitored every hour post oedema induction for 5 hours and the percentage of inhibited oedema were calculated. Results The inhibitory percentage exhibited by Gardenia carinata water extract (GCWE) was 32.66%, G. carinata methanol extract (GCME) was 27.98% and G. carinata chloroform extract (GCCE) 24.41% respectively. All these groups are significantly differenced in inhibition when compared with indomethacin inhibition percentage 39.33% at the fifth hour (p < 0.05). Extracts of G. carinata leaves revealed the presence of flavonoids, terpenoids, tannins, phenolic compounds and saponins. Conclusion Gardenia carinata leaves showed the anti-inflammatory activity in carrageenan-induced rat paw oedema model.
- Open Access
- 1 January 2018
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9
Phytochemical investigation and evaluation of antimicrobial activity of different extracts of Swietenia macrophylla barks
Background The plant Swietenia macrophylla possesses therapeutic uses like antibacterial, antifungal, antidiarrhoeal, anti-inflammatory, hypoglycaemic, antioxidant, cytotoxic, antimalarial and antidiabetic activities. The purpose of this study is to determine the phytochemical composition and antimicrobial activity of two different extracts of S. macrophylla bark against six bacterial strains. Methods Swietenia macrophylla bark powder was extracted by Soxhlet extraction method by using acetone and methanol. The extract was characterised by Shinoda test, Fehling’s test, Wagner’s test and Biuret test. Different concentration (10 and 20 mg/mL) of plant extracts were tested by agar well diffusion method by using bacterial strains Bacillus subtilis, Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus vulgaris and compared with tetracycline (0.05 mg/mL). Results Extracts of S. macrophylla barks revealed the presence of flavonoids, alkaloids, phenolic compounds, carbohydrates, proteins, fats and oils. The most susceptible bacterial strains were P. aeruginosa and S. aureus for methanol extract and acetone extract respectively. Antibacterial screening with acetone and methanol extracts showed both significant (p0.05) zone of inhibition. The MIC was found in the range between 0.63 to 2.50 mg/mL. Conclusion Swietenia macrophylla bark showed that it has broad spectrum of antimicrobial activity that appear as potential alternative therapeutic agent against certain microorganisms in future drug development.
- 1 January 2018
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9
Open AccessPhytochemical investigation and evaluation of antimicrobial activity of different extracts of Swietenia macrophylla barks
Background The plant Swietenia macrophylla possesses therapeutic uses like antibacterial, antifungal, antidiarrhoeal, anti-inflammatory, hypoglycaemic, antioxidant, cytotoxic, antimalarial and antidiabetic activities. The purpose of this study is to determine the phytochemical composition and antimicrobial activity of two different extracts of S. macrophylla bark against six bacterial strains. Methods Swietenia macrophylla bark powder was extracted by Soxhlet extraction method by using acetone and methanol. The extract was characterised by Shinoda test, Fehling’s test, Wagner’s test and Biuret test. Different concentration (10 and 20 mg/mL) of plant extracts were tested by agar well diffusion method by using bacterial strains Bacillus subtilis, Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus vulgaris and compared with tetracycline (0.05 mg/mL). Results Extracts of S. macrophylla barks revealed the presence of flavonoids, alkaloids, phenolic compounds, carbohydrates, proteins, fats and oils. The most susceptible bacterial strains were P. aeruginosa and S. aureus for methanol extract and acetone extract respectively. Antibacterial screening with acetone and methanol extracts showed both significant (p0.05) zone of inhibition. The MIC was found in the range between 0.63 to 2.50 mg/mL. Conclusion Swietenia macrophylla bark showed that it has broad spectrum of antimicrobial activity that appear as potential alternative therapeutic agent against certain microorganisms in future drug development.